医学
内科学
贝里穆马布
安慰剂
安慰剂对照研究
随机对照试验
系统性红斑狼疮
临床试验
不利影响
析因分析
临床终点
作者
Katerina Chatzidionysiou,Evangelia Samoli,Petros P. Sfikakis,Maria G Tektonidou
标识
DOI:10.1136/annrheumdis-2020-218444
摘要
We thank Dr Bettiol et al 1 for their interest in our article.2 Dr Bettiol et al performed a post-hoc analysis on a different randomised controlled trial of subcutaneous belimumab in systemic lupus erythematosus (SLE). The authors evaluated the effect of treatment with belimumab on the levels of anticardiolipin antibodies (aCL) (IgG, IgM and IgA) but also of anti-β2-glycoprotein I (antiβ2GPI) antibodies. The latter was unfortunately not available in BLISS-76 and BLISS-52 trials, as acknowledged in the limitations of our post-hoc analysis. The authors have also extended our observation about the effect of co-treatment with antimalarials on antiphospholipid antibody (aPL) titres in the belimumab versus the placebo group, by examining the duration of their use. We agree with the authors that the duration of antimalarials is of high clinical significance. In addition to previous retrospective studies,3 we have recently shown in …
科研通智能强力驱动
Strongly Powered by AbleSci AI